Late last year, the UK and EU agreed a free trade agreement (FTA) for goods, without quotas or tariffs. It was welcomed on both sides, but with caution. No deal was avoided, but the detail has yet to be seen and the long term effects yet to manifest themselves.
For the medtech sector, the deal was effectively a hard Brexit, with the UK placed outside the EU medtech regulatory system and needing to develop its own standalone system, administered...